对于已发病的头支状细胞癌,IO Biotech公司的IO102-IO103癌症疫苗与默克公司的KEYTRUDA药物显示出有前途的第二期结果. IO Biotech's cancer vaccine IO102-IO103 with Merck's KEYTRUDA showed promising Phase 2 results for advanced head and neck squamous cell carcinoma.
对于其癌症疫苗IO102-IO103与默克的KEYTRUDA (pembrolizumab) 结合用于晚期头皮细胞癌的第二阶段试验,IO Biotech报告了有希望的结果. IO Biotech reported promising Phase 2 trial results for its cancer vaccine IO102-IO103 combined with Merck's KEYTRUDA (pembrolizumab) for advanced squamous cell carcinoma of the head and neck. 研究显示,PD-L1表达率高的病人的总体答复率为44.4%,中位无进步状态的存活率为6.6个月。 The study showed a 44.4% overall response rate and a median progression-free survival of 6.6 months among patients with high PD-L1 expression. 与以往调查结果一致的安全情况说明表明,这种结合可能会提高具有挑战性癌症的治疗结果。 The safety profile aligned with previous findings, suggesting this combination may enhance treatment outcomes for challenging cancers.